Search

Tandutinib

Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. … Phase I/II trials are underway.

LErafAON

NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation … Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.

Sarocladium strictum

Sarocladium strictum allergenic extract is used in allergenic testing.

Tropisetron

Tropisetron is an indole derivative with antiemetic activity. … As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting

Butyrylcholinesterase

SQ-109

SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. … Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.

PX-102

PX-102 is under investigation in clinical trial NCT01998672 (Multiple Ascending Oral Dose Phase I Study With Px-102).

Alvocidib

Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer. … It works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells.

VGV-1

VGV-1 is a potential salvage therapy for treatment of HIV infected people who have failed anti-retroviral therapy.

Norclozapine

ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. … It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.